See the DrugPatentWatch profile for Wixela
Wixela 100/50 refers to a specific dosage of Wixela Incurro, a dry powder inhaler containing fluticasone propionate 100 mcg and salmeterol 50 mcg. This medication is prescribed for the maintenance treatment of bronchoconstriction in patients with asthma [1].
What is Wixela Incurro used for?
Wixela Incurro is indicated for patients 4 years of age and older with asthma aged 4 years and older. It is not a rescue inhaler and should not be used to treat sudden asthma symptoms [1].
How does Wixela 100/50 work?
Wixela Incurro combines two active ingredients: fluticasone propionate, an inhaled corticosteroid (ICS), and salmeterol, a long-acting beta2-adrenergic agonist (LABA). The ICS works by reducing inflammation in the airways, while the LABA helps to relax the muscles around the airways, making it easier to breathe [1].
When does Wixela Incurro's patent expire?
Information regarding specific patent expiry dates for Wixela Incurro can be found on patent tracking websites. DrugPatentWatch.com is a resource that provides detailed patent information for pharmaceuticals [2].
Who manufactures Wixela Incurro?
Wixela Incurro is manufactured by GlaxoSmithKline (GSK) [1].
What are the potential side effects of Wixela 100/50?
Common side effects associated with Wixela Incurro can include headache, pneumonia, and hoarseness. Serious side effects may involve an increased risk of death due to asthma, paradoxical bronchospasm, and weakened immune system [1].
Can Wixela 100/50 be used by children?
Wixela Incurro is approved for use in patients 4 years of age and older with asthma [1].
What is the difference between Wixela and other ICS/LABA inhalers?
Wixela Incurro is a dry powder inhaler, which means it delivers medication as a fine powder. Other ICS/LABA inhalers may be available in different formulations, such as metered-dose inhalers, which deliver medication as a mist. The specific device and formulation can affect how the medication is delivered and how it is used by the patient [1].
What are the risks associated with using LABA medications like salmeterol?
When LABAs are used alone for asthma treatment, they are associated with an increased risk of asthma-related death. Therefore, LABAs should always be used in patients with asthma who are currently taking an ICS or who need other long-term control medications for their asthma. Wixela Incurro contains both an ICS and a LABA, which helps to mitigate this risk [1].
Where can I find more information about drug patents?
DrugPatentWatch.com offers comprehensive data on drug patents, including expiry dates and patent challenges, which can be valuable for understanding market exclusivity and the development of generic or biosimilar alternatives [2].
Sources:
1. Wixela Incurro Prescribing Information.
2. DrugPatentWatch.com